Roche’s Amyloid-Targeting Alzheimer’s Drug Fails in Phase II Trial

Roche and Genentech released data from their Phase II API-ADAD trial showing their experimental Alzheimer’s disease drug crenezumab failed to prevent or reduce the cognitive decline that is indicative of the disease. The drug’s failure represents another setback to the growing number of experimental drugs targeting amyloid-beta plagues, protein aggregates involved in the disease process.

According to, “More recently, Biogen’s ephemeral success with Aduhelm spurred big hopes that a drug that effectively cut levels of the toxic amyloid beta could go on to earn billions. But after Medicare extinguished any hopes that an amyloid drug could earn billions without solid human efficacy and safety data, sentiment began to turn negative again.”

To learn more, click here.

(Source: Endpoints News, June 16^th, 2022)